Cohance Lifesciences' Pashamylaram Facility Gets USFDA EIR With VAI Status
Hyderabad: Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced that the United States Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Pashamylaram, Hyderabad.
In a regulatory disclosure,the company stated that the USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI). The inspection was conducted at the facility bearing FEI No. 1000623515.
The company’s latest update follows its earlier communication dated August 5,2026,regarding the USFDA inspection of the Pashamylaram manufacturing facility.
With the issuance of the Establishment Inspection Report, the USFDA inspection has been officially concluded.
Next Story